ライフサイエンスコーパス: alanine transaminase

1 nd elevated plasma malondialdehyde (MDA) and alanine transaminase.

2 id not induce splenomegaly or increase serum alanine transaminase.

3 05, -0.02; P = 1.4 x 10(-6)) and with higher alanine transaminase (0.02 [0.01, 0.03]; P = 0.002) and

4 actate dehydrogenase ([1-(13)C]lactate), and alanine transaminase ([1-(13)C]alanine) was assessed.

5 transaminase 15.0% (95% CI, 13.6%-16.5%) and alanine transaminase 15.0% (95% CI, 13.6%-16.4%).

6 GPT2 [also known as alanine transaminase 2 (ALT2)] is one of two related tra

7 Multivariable analysis suggested that 2-h alanine transaminase, 2-h lactate, 11 to 29 mmol supplem

8 severe hepatocellular injury with jaundice (alanine transaminase 2474 IU/L and total bilirubin 141 u

9 caspofungin vs 9 fluconazole), and elevated alanine transaminase (4 caspofungin vs 8 fluconazole).

10 reference range, 0-31 U/L [0-0.52 mukat/L]), alanine transaminase (70 U/L [1.17 mukat/L]; reference r

11 reference range, 0-31 U/L [0-0.52 mukat/L]), alanine transaminase (70 U/L [1.17 mukat/L]; reference r

12 enes decreased in organs with high perfusate alanine transaminase, a biomarker associated with advers

13 associated with higher circulating levels of alanine transaminase, a marker of liver injury, and with

14 lents per ml) and transiently elevated serum alanine transaminase activities were present from weeks

15 ied breads decreased triglyceride levels and alanine transaminase activity and caused an increase in

16 istry based on blood urea nitrogen levels or alanine transaminase activity--was observed in doses up

17 function tests (aspartate aminotransferase, alanine transaminase, alkaline phosphatase, and total bi

18 and portal inflammation, and elevated serum alanine transaminase/alkaline phosphatase levels).

19 Except for ALT (alanine transaminase), all GRSs were significantly assoc

20 gamma-Glutamyl transpeptidase (28%) and alanine transaminase (ALT) (27%) were the most frequentl

21 ndex (BMI) (aOR, 1.58 per 1 kg/m2; P < .01), alanine transaminase (ALT) (aOR, 1.76 per 10 U/L; P < .0

22 apy, 8 of 19 (42%) patients had normal serum alanine transaminase (ALT) (complete responders).

23 e undergoing phlebotomy, we found that serum alanine transaminase (ALT) activities decreased but by l

24 tioxidant concentrations with abnormal serum alanine transaminase (ALT) activity in a large, national

25 Plasma alanine transaminase (ALT) activity, liver histology, an

26 l evaluable patients, accompanied by reduced alanine transaminase (ALT) activity.

27 ear regression to assess the associations of alanine transaminase (ALT) and alkaline phosphatase (ALP

28 ociation of rs72613567 with plasma levels of alanine transaminase (ALT) and clinical liver disease an

29 red acetaminophen overdose with normal serum alanine transaminase (ALT) and creatinine on presentatio

30 re sensitivity to report liver injury versus alanine transaminase (ALT) and International Normalized

31 es mild steatosis, slight elevation of serum alanine transaminase (ALT) and little or no inflammation

32 Normalization of serum alanine transaminase (ALT) concentration (biochemical re

33 icacy was assessed by normalization of serum alanine transaminase (ALT) concentration and decrease in

34 rs (NRs) according to normalization of serum alanine transaminase (ALT) during treatment and follow-u

35 9 because of evidence of increased levels of alanine transaminase (ALT) in patients receiving the hig

36 or 9 weeks exacerbated an increase in plasma alanine transaminase (ALT) levels (227 +/- 75 vs. 140 +/

37 f hepatotoxicity as evidenced by lower serum alanine transaminase (ALT) levels (28 +/- 1 IU/L and 770

38 patients in the 10 MU group normalized serum alanine transaminase (ALT) levels and 59% had no hepatit

39 Elevated alanine transaminase (ALT) levels and low serum hepatiti

40 Serum alanine transaminase (ALT) levels are used to select hep

41 Elevated serum alanine transaminase (ALT) levels at 6 hours confirmed h

42 Ethanol increased serum alanine transaminase (ALT) levels from 30 +/- 6 to 64 +/

43 reased liver to body weight ratios and serum alanine transaminase (ALT) levels in AdlacZ-treated anim

44 CL (VE-CL, 1 mg/mouse) significantly lowered alanine transaminase (ALT) levels in CCl4-treated mice (

45 evels have been associated with raised serum alanine transaminase (ALT) levels in hepatitis C virus (

46 compared females versus males with elevated alanine transaminase (ALT) levels in the chronic HCV pat

47 reased liver-to-body weight ratios and serum alanine transaminase (ALT) levels in wild-type mice (109

48 Group B patients had lower mean serum alanine transaminase (ALT) levels than group A patients

49 Although a rise in alanine transaminase (ALT) levels was present at the tim

50 nol elevated liver:body weight ratios, serum alanine transaminase (ALT) levels, and pathology scores

51 ccur in patients with MAFLD, irrespective of alanine transaminase (ALT) levels, and ultrasound gradin

52 ry endpoints included normalization of serum alanine transaminase (ALT) levels, disappearance of hepa

53 ly elevated aspartate transaminase (AST) and alanine transaminase (ALT) levels, indicative of severe

54 Serum alanine transaminase (ALT) levels, liver histology, hepa

55 stratification based on 2 consecutive serum alanine transaminase (ALT) levels.

56 y was defined by persistently elevated serum alanine transaminase (ALT) levels.

57 epatitis C virus (HCV) infection have normal alanine transaminase (ALT) levels.

58 shed neither I/R-induced elevations in serum alanine transaminase (ALT) nor AP-1 activation.

59 CBT protocol did not predict the peak serum alanine transaminase (ALT) observed in the patients.

60 The liver enzymes, alanine transaminase (ALT) or aspartate transaminase (AS

61 (87%) were asymptomatic, detected by routine alanine transaminase (ALT) or HCV monitoring.

62 Peak alanine transaminase (ALT) ranged from 6 to 5927 U/L (me

63 36, P =.0001) and negatively correlated with alanine transaminase (ALT) values (-0.178, P =.0001), du

64 study included 24 patients with normal serum alanine transaminase (ALT) values before therapy who had

65 virological complete responders had elevated alanine transaminase (ALT) values.

66 Median peak serum alanine transaminase (ALT) was 1,640 U/L (698-2,565 U/L)

67 perform genetic analysis on serum levels of alanine transaminase (ALT), alkaline phosphatase (ALP) a

68 ipoprotein (LDL) cholesterol, triglycerides, alanine transaminase (ALT), and aspartate transaminase (

69 n mean serum levels of alkaline phosphatase, alanine transaminase (ALT), and gamma-glutamyl transpept

70 h Study, for whom levels of plasma fetuin-A, alanine transaminase (ALT), and gamma-glutamyltranspepti

71 on) as well as aspartate transaminase (AST), alanine transaminase (ALT), and lactic dehydrogenase (LD

72 as reflected in phospho-c-jun levels, serum alanine transaminase (ALT), and liver histology were ass

73 atched with respect to age, sex, race, serum alanine transaminase (ALT), and liver histology.

74 levels of aspartate aminotransferase (AST), alanine transaminase (ALT), and mitochondrial aspartate

75 entify MetS using serum liver function tests-Alanine Transaminase (ALT), Aspartate Aminotransferase (

76 MA-IR), uric acid, C-reactive protein (CRP), alanine transaminase (ALT), aspartate transaminase (AST)

77 patitis was associated with lower peak serum alanine transaminase (ALT), aspartate transaminase, and

78 Monitoring of alanine transaminase (ALT), creatinine, and full blood c

79 eflected by gamma-glutamyltransferase (GGT), alanine transaminase (ALT), fetuin-A, and the algorithm-

80 d for natural log (ln)-transformed values of alanine transaminase (ALT), gamma-glutamyltransferase (G

81 iver damage by alcohol was worse with higher alanine transaminase (ALT), more immune cell infiltratio

82 enzymatic assay targets alanine and employs alanine transaminase (ALT), pyruvate oxidase (POx), and

83 CP, rheumatoid factor (RF) titer, and serum alanine transaminase (ALT).

84 s, 1 with elevated and the other with normal alanine transaminase (ALT).

85 ium; potassium; aspartate transferase (AST); alanine transaminase (ALT); alkaline phosphatase (ALP);

86 ), cholesterol (-48%), triglycerides (-76%), alanine transaminase (ALT: -79%), and liver weight (-43%

87 ields [HPF]) and severe liver injury (plasma alanine transaminase [ALT] activities: 4,120 +/- 960 U/L

88 ansaminase (aspartate transaminase [AST] and alanine transaminase [ALT]) and prothrombin time (PT) va

89 were measured and compared with biochemical (alanine transaminase [ALT]) and viral (HCV RNA) indicato

90 tantial necrosis (38% +/- 3% of hepatocytes; alanine transaminase [ALT]: 1,500 +/- 300 U/L) at 7 hour

91 = 2 x 10(-10)) was associated with levels of alanine transaminase, an indicator of liver damage.

92 ease in midazolam clearance with increase in alanine transaminase and a lower clearance of the glucur

93 an +/- standard deviation (SD) decreases for alanine transaminase and aspartate aminotransferase at w

94 e DMN-induced changes in the serum levels of alanine transaminase and aspartate transaminase (p<0.05)

95 Alanine transaminase and aspartate transaminase levels f

96 Asymptomatic transient increases in alanine transaminase and aspartate transaminase were obs

97 ubjects, and a reversible increase in plasma alanine transaminase and aspartic transaminase levels in

98 Higher levels of alanine transaminase and interleukin 10 were also associ

99 is work confirms the importance of perfusate alanine transaminase and lactate at 2-h, as well as the

100 parallel with the hepatocyte marker enzymes alanine transaminase and lactate dehydrogenase.

101 entified dadRAX locus encoding the regulator alanine transaminase and racemase coupled with SpuC, the

102 gastroduodenal ulcers and elevated levels of alanine transaminase and total bilirubin in patients rec

103 osis, triglycerides, aspartate transaminase, alanine transaminase, and stellate cell proliferation by

104 trogen) and hepatic (aspartate transaminase, alanine transaminase, and total bilirubin) function in 3

105 nd had reduced serum levels of IFN-gamma and alanine transaminase as well as decreased expression of

106 ) and liver toxicity (proportion of patients alanine transaminase, aspartate aminotransferase and Alk

107 stay, and evaluation of serum transaminases (alanine transaminase, aspartate aminotransferase) and co

108 ls of serum bilirubin, alkaline phosphatase, alanine transaminase, aspartate transaminase, and bile a

109 like total leucocyte count, urea, bilirubin, alanine transaminase, aspartate transaminase, internatio

110 Elevated alanine transaminase/aspartate transaminase was seen in

111 llitus (P =.009), and aspartate transaminase/alanine transaminase (AST/ALT) ratio greater than 1 (P =

112 Serum levels of aspartate and alanine transaminases (AST and ALT) were mildly elevated

113 tolic blood pressure, serum cholesterol, and alanine transaminase at 12 months.

114 tosis (beta = 0.021; P = 3 x 10(-4)), higher alanine transaminase (beta = 0.002; P = 3 x 10(-5)), low

115 Alanine transaminase, bilirubin, and survival were deter

116 the serum levels of aspartate transaminase, alanine transaminase, blood urea nitrogen, and creatinin

117 chest x-ray findings, PaO2/FiO2, creatinine, alanine transaminase, cancer, cardiac arrest, chronic he

118 discontinued because of grade 3 or 4 raised alanine transaminase concentrations in 19 of 662 individ

119 LT, the mean peak aspartate transaminase and alanine transaminase concentrations in group A (1, 444.1

120 The duration of follow-up and serum alanine transaminase correlated with liver stiffness, an

121 -C), and hepatic (aspartate transaminase and alanine transaminase) damage and of decongestion (N-term

122 Alanine transaminase elevation > 5 x the UNL was observe

123 One infant (5.9%) experienced an alanine transaminase elevation >3 to 5x the upper limit

124 ild, transient events were tachycardia in 1, alanine transaminase elevation in 1, and hyperglycemia i

125 Aspartate and alanine transaminase elevations occurring before treatme

126 tudy was extended to monitor the activity of alanine transaminase enzyme, a key biomarker for the det

127 reater inflammatory cell infiltration, serum alanine transaminase, expression of hepatic inflammatory

128 These markers were predictors of severe alanine transaminase flares, after treatment withdrawal,

129 The mitochondrial alanine transaminase GPT2 was found to be necessary and

130 ither a hepatic safety event (an increase in alanine transaminase >3 times the upper limit of normal

131 Transient increases in alanine transaminase, hepatocyte apoptosis, and prolifer

132 TRA and arsenic trioxide group, raised liver alanine transaminase in 11 (10%) of 108 versus 27 (25%)

133 y as manifested by increased blood levels of alanine transaminase in common for most of the eight com

134 were decreases in aspartate transaminase and alanine transaminase in the above-normal groups from 121

135 events occurred in 84% of neutropenia (32%), alanine transaminase increase (20%), aspartate transamin

136 kinase increase (30 [12%] vs one [<1%]), and alanine transaminase increase (28 [11%] vs 15 [6%]).

137 After 42 hr, alanine transaminase increased eightfold after RSLT and

138 ajority preferred aspartate transaminase and alanine transaminase less than 50 IU/mL.

139 nd NIM811, diminished the elevation of serum alanine transaminase level after I/R injury (174.0+/-28.

140 No consistent relationship between alanine transaminase level and TTV DNA level was observe

141 to spleen density of 1.0 or less, (2) serum alanine transaminase level greater than 30 U/L, and (3)

142 30 U/L, and (3) serum aspartate transaminase/alanine transaminase level less than 1.0.

143 ically significant (>/=grade 3) increases in alanine transaminase level or decreases in neutrophil co

144 ex situ perfusion, at which point perfusate alanine transaminase level was 1152 IU/L and urea concen

145 ad been hospitalized for 9 days; predonation alanine transaminase level was 63 IU/L, and the period f

146 Systolic blood pressure, lactate level, alanine transaminase level, and systemic pH were signifi

147 ence of diabetes and hypertension, and lower alanine transaminase levels (P < .001 for all).

148 FN-gamma secreting and which correlated with alanine transaminase levels (r2 = 0.45; P = .001), were

149 ptible to AILI, as indicated by higher serum alanine transaminase levels and mortality.

150 nd OASL1(-/-) mice consistently showed lower alanine transaminase levels and pro-inflammatory cytokin

151 enome equivalents per ml) for >2 years, with alanine transaminase levels becoming elevated again befo

152 ation disease, which is defined by a rise in alanine transaminase levels during ART.

153 as associated with stable or declining serum alanine transaminase levels in 4 patients.

154 and the assessed nontransplanted grafts were alanine transaminase levels of 53 U/L (34-68 U/L) versus

155 titis in tamarins characterized by increased alanine transaminase levels that quickly return to norma

156 Serum alanine transaminase levels were increased in all BDL mi

157 Alanine transaminase levels were significantly elevated

158 t body fat, fasting blood glucose, and serum alanine transaminase levels with foveal vessel density,

159 nd in the general population (P < 10(-7) for alanine transaminase levels).

160 Markers of liver injury, including serum alanine transaminase levels, apoptosis, hepatic fat load

161 The serum alanine transaminase levels, terminal deoxynucleotidyl t

162 lular injury, accompanied by increased serum alanine transaminase levels.

163 al load (median 11-25 IU/ml) and have normal alanine transaminase levels.

164 r graft failure included log creatinine, log alanine transaminase, log aspartate transaminase, UNOS s

165 posure, hepatic oxidative insult, nor plasma alanine transaminase marking hepatocyte damage.

166 re not significantly affected; elevations in alanine transaminase occurred in combination with atazan

167 ory infection (20/0), pneumonia (13/10), and alanine transaminase or aspartate transaminase elevation

168 erence in incidence rates for an increase in alanine transaminase or total bilirubin between both CSL

169 dels, SF was associated with LIC (P = .006), alanine transaminase (P = .025), and weight (P = .026).

170 y to have higher body mass index (P = 0.04), alanine transaminase (P = 0.0001), alkaline phosphatase

171 specimens collected within 2 weeks after the alanine transaminase peak, at the end of the original st

172 ed key intermediate in biologically relevant alanine transaminase reactions.

173 Compared with WT, JNK2 KO mice had 38% less alanine transaminase release and 39% less necrosis by hi

174 1 +/- 36, PUGNAc: 42 +/- 22 pg/mL, p < .05), alanine transaminase (sham surgery: 95 +/- 14, control:

175 unt (1 x 10(3)), alkaline phosphatase (U/L), alanine transaminase (U/L), aspartate aminotransferase (

176 LP), leukogram, and dosages of aspartate and alanine transaminases, urea, and creatinine.

177 ntent correlated with waist-to-height ratio, alanine transaminase, uric acid, serum triglycerides, an

178 The median posttransplant peak in alanine transaminase was 1136 U/L (220-6683 U/L).

179 ration, monocyte/macrophage cfDNA levels and alanine transaminase was able to correctly identify GVHD

180 entrations of aspartate aminotransferase and alanine transaminase were greater, while serum albumin a

181 e hepatic enzymes aspartate transaminase and alanine transaminase were significantly greater in patie

182 r BMI, waist circumference, waist-hip ratio, alanine transaminase, white blood cell count and lower h